Literature DB >> 3379209

Prevalence of congenital cardiac anomalies at high altitude.

C Y Miao1, J S Zuberbuhler, J R Zuberbuhler.   

Abstract

The effect of high altitude on the prevalence of congenital heart disease was tested by examining 1,116 school children at four study sites in the People's Republic of China. Sites ranged in altitude from sea level to 4,500 m above sea level. Children were screened by physical examination, and an echocardiogram and electrocardiogram were performed on each child suspected of having a cardiac anomaly. A high prevalence of patent ductus arteriosus and atrial septal defect was found at the three high altitude sites and the effect of altitude was progressive. Both anomalies were postulated to be the result of the lower atmospheric oxygen tension present at high altitude. Failure of lower oxygen tension to constrict the ductus is thought to be the mechanism in patent ductus arteriosus. It is theorized that the persistence of high pulmonary vascular resistance and high right heart pressures at high altitude inhibits early closure of the foramen ovale. Subsequent growth may result in stretching of the fossa ovalis and incompetence of the flap and may produce an atrial septal defect. The high prevalence of atrial septal defect in tetralogy of Fallot is cited as a possible analogy because right ventricular pressure is high and right ventricular compliance is low from birth.

Entities:  

Mesh:

Year:  1988        PMID: 3379209     DOI: 10.1016/0735-1097(88)90378-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  23 in total

Review 1.  Heart valve development: endothelial cell signaling and differentiation.

Authors:  Ehrin J Armstrong; Joyce Bischoff
Journal:  Circ Res       Date:  2004-09-03       Impact factor: 17.367

2.  Patent ductus arteriosus: an overview.

Authors:  James E Dice; Jatinder Bhatia
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

Review 3.  Neonatal oxygenation, pulmonary hypertension, and evolutionary adaptation to high altitude (2013 Grover Conference series).

Authors:  Susan Niermeyer; Mario Patricio Andrade-M; Enrique Vargas; Lorna G Moore
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 4.  Prenatal programming of pulmonary hypertension induced by chronic hypoxia or ductal ligation in sheep.

Authors:  Demosthenes G Papamatheakis; Madalitso Chundu; Arlin B Blood; Sean M Wilson
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

Review 5.  Congenital heart disease and pulmonary arterial hypertension in South America (2013 Grover Conference series).

Authors:  Antonio Augusto Lopes; Patricia C Flores; Gabriel F Diaz; Sonia M F Mesquita
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

6.  Risk Factors of Congenital Heart Diseases: A Case-Control Study inNorthwest Iran.

Authors:  Mohammad Naghavi-Behzad; Mahasti Alizadeh; Saber Azami; Shirin Foroughifar; Khazar Ghasempour-Dabbaghi; Nazila Karzad; Hamid-Reza Ahadi; Ali Naghavi-Behzad
Journal:  J Cardiovasc Thorac Res       Date:  2013-03-14

Review 7.  Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period.

Authors:  Jeff Reese; Alex Veldman; Lisa Shah; Megan Vucovich; Robert B Cotton
Journal:  Semin Perinatol       Date:  2010-06       Impact factor: 3.300

8.  Disruption of spatiotemporal hypoxic signaling causes congenital heart disease in mice.

Authors:  Xuejun Yuan; Hui Qi; Xiang Li; Fan Wu; Jian Fang; Eva Bober; Gergana Dobreva; Yonggang Zhou; Thomas Braun
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

9.  Differences by Altitude in the Frequency of Congenital Heart Defects in Colombia.

Authors:  Alberto García; Karen Moreno; Miguel Ronderos; Néstor Sandoval; Mónica Caicedo; Rodolfo J Dennis
Journal:  Pediatr Cardiol       Date:  2016-08-26       Impact factor: 1.655

Review 10.  Antenatal hypoxia and pulmonary vascular function and remodeling.

Authors:  Demosthenes G Papamatheakis; Arlin B Blood; Joon H Kim; Sean M Wilson
Journal:  Curr Vasc Pharmacol       Date:  2013-09       Impact factor: 2.719

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.